Table I.
Characteristic of patients on BRAF inhibitors
| Characteristic | Patient no.
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
| Age, y | 46 | 64 | 47 | 60 | 54 | 53 | 55 | 58 | 69 | 77 | 68 | 64 | 83 | 57 |
| Sex | F | M | F | F | F | M | F | F | F | M | F | M | F | M |
| Targeted therapy | V | V | V | V | V | D + T | V | V | V | V | D | D + T; V | V | V |
| Time before first skin lesion, wk | 12 | 5 | 20 | 56 | 12 | 19 | 4 | 10 | 5 | 3 | 8 | 14 | 1 | 8 |
| History of SCC | + | + | − | − | − | − | + | − | − | − | − | − | − | − |
| Type of lesion | ||||||||||||||
| SCC | + | + | − | + | + | − | + | − | + | − | + | − | + | − |
| SCC, KA type | + | − | − | + | − | − | − | − | − | − | + | − | + | − |
| Verrucous keratosis | + | + | + | − | + | + | − | + | + | + | + | + | + | + |
| Acantholytic dyskeratosis | + | − | + | + | − | − | + | − | + | + | + | + | − | − |
| Eruptive nevi | − | − | − | − | − | − | − | − | − | − | − | − | − | + |
D, Dabrafenib (GSK2118436); F, female; KA, keratoacanthoma; M, male; SCC, squamous cell carcinoma; T, trametinib (GSK1120212); V, vemurafenib.